<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998958</url>
  </required_header>
  <id_info>
    <org_study_id>CR102968</org_study_id>
    <secondary_id>2013-004005-11</secondary_id>
    <secondary_id>JNJ-54135419</secondary_id>
    <secondary_id>ESKETINTRD2003</secondary_id>
    <nct_id>NCT01998958</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression</brief_title>
  <acronym>SYNAPSE</acronym>
  <official_title>A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and dose response of intranasal
      esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with
      placebo in improving depressive symptoms in participants with treatment-resistant depression
      (TRD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 2-panel, randomized ( participants are assigned different treatments based on
      chance), double-blind (neither investigator nor participant knows which treatment the
      participant receives), placebo-controlled (placebo is an inactive substance that is compared
      with a drug to test whether the drug has a real effect in a clinical trial), multicenter
      study. Approximately 100 male and female adult participants diagnosed with TRD will
      participate in this study. For participants in both panels (Panel A and Panel B), there will
      be 4 study phases: a 4-week screening phase, a double-blind treatment phase (Day 1 to Day
      15), an optional open-label treatment phase (Panel A: Day 15 to 74; Panel B: Day 15 to 25),
      and an 8-week post-treatment (follow-up) phase. Depending on the treatment Panel, patients
      will be assigned to intranasal placebo or intranasal esketamine 14 mg, 28 mg, 56 mg, or 84
      mg. Safety assessments will be performed throughout the study. The maximum study duration for
      a participant will be 23 weeks for Panel A and 16 weeks for Panel B.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2014</start_date>
  <completion_date type="Actual">September 25, 2015</completion_date>
  <primary_completion_date type="Actual">July 21, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 1) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Day 8- Analysis of Covariance (ANCOVA) Analysis</measure>
    <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
    <description>MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 8) in Montgomery Asberg Depression Rating Scale Total Score at Day 15- ANCOVA Analysis</measure>
    <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
    <description>MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Have Completed the Double-Blind Phase and Received the Same Treatment for Both Periods</measure>
    <time_frame>Day 2 Up to Day 15</time_frame>
    <description>Sustained response was defined as at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Received the Same Treatment for Both Periods, Including Participants Who Did Not Complete the Double-blind Phase</measure>
    <time_frame>Day 2 Up to Day 15</time_frame>
    <description>Sustained response was defined as at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Percentage of Participants With Response Based on MADRS Total Score</measure>
    <time_frame>Period 1: Days 1 (2 hour), 2 and 8 of Double-blind Phase</time_frame>
    <description>A participant is defined a responder at a given time point if the percent improvement in MADRS is greater than or equal to (&gt;=) 50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Percentage of Participants With Response Based on MADRS Total Score</measure>
    <time_frame>Period 2: Days 1 (2 hour), 2 and 8 of Double-blind Phase</time_frame>
    <description>A participant is defined a responder at a given time point if the percent improvement in MADRS is &gt;=50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Percentage of Participants in Remission Based on MADRS Total Score at Days 1, 2 and 8 of Double-blind Phase</measure>
    <time_frame>Days 1, 2 and 8 of Double-blind Phase of Period 1</time_frame>
    <description>Participants who had a MADRS total score of &lt;=10 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Percentage of Participants in Remission Based on MADRS Total Score at Days 1, 2 and 8 of Double-blind Phase</measure>
    <time_frame>Days 1, 2 and 8 of Double-blind Phase of Period 2</time_frame>
    <description>Participants who had a MADRS total score of less than or equal to (&lt;=10) were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 1) in Quick Inventory of Depressive Symptomatology-16-item Self Report (QIDS-SR16) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis</measure>
    <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
    <description>QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 8) in Quick Inventory of Depressive Symptomatology-16-item Self Report Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis</measure>
    <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
    <description>QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 1) in Clinical Global Impression - Severity (CGI-S) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</measure>
    <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
    <description>CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 8) in Clinical Global Impression - Severity Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</measure>
    <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
    <description>CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 1) in Generalized Anxiety Disorder (GAD-7) Total Score at Day 8 (Double-Blind Treatment Phase) ANCOVA Analysis</measure>
    <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
    <description>GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 8) in Generalized Anxiety Disorder-7 Total Score at Day 15 (Double-Blind Treatment Phase)- ANCOVA Analysis</measure>
    <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
    <description>GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 1) in Patient Global Impression of Severity (PGI-S) Score Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</measure>
    <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
    <description>PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel A and B: Change From Baseline (Day 8) in Patient Global Impression of Severity Score Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</measure>
    <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
    <description>PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. A negative change in score indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Treatment Resistant Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Esketamine 14 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esketamine 28 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esketamine 56 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esketamine 84 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine 14 mg</intervention_name>
    <description>1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days</description>
    <arm_group_label>Esketamine 14 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine 28 mg</intervention_name>
    <description>1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days</description>
    <arm_group_label>Esketamine 28 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine 56 mg</intervention_name>
    <description>1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days</description>
    <arm_group_label>Esketamine 14 mg</arm_group_label>
    <arm_group_label>Esketamine 28 mg</arm_group_label>
    <arm_group_label>Esketamine 56 mg</arm_group_label>
    <arm_group_label>Esketamine 84 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine 84 mg</intervention_name>
    <description>1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days</description>
    <arm_group_label>Esketamine 84 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase</description>
    <arm_group_label>Esketamine 14 mg</arm_group_label>
    <arm_group_label>Esketamine 28 mg</arm_group_label>
    <arm_group_label>Esketamine 56 mg</arm_group_label>
    <arm_group_label>Esketamine 84 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        --Participant must meet Diagnostic and Statistical Manual of Mental Disorders -Fourth
        Edition -Text Revised (DSM-IV-TR) diagnostic criteria for Major Depressive Disorder (MDD),
        without psychotic features, based upon clinical assessment, and confirmed by the Mini
        International Neuropsychiatric Interview (MINI)-Participant's major depressive episode and
        treatment response must be deemed &quot;valid&quot; by remote independent raters-Participant must
        have had an inadequate response to at least 2 antidepressants, at least one of which is in
        the current episode of depression; the antidepressant treatment response questionnaire
        (ATRQ) will be used to assess antidepressant treatment response during the current episode;
        prior medication history will be used to determine antidepressant treatment response in
        prior episode(s) -Have an Inventory of Depressive Symptoms-Clinician rated, 30-item
        (IDS-C30) total score &gt;=34 at Screening and predose at Day 1

        Exclusion Criteria:

        -Participant has a current DSM-IV-TR diagnosis of bipolar and related disorders,
        intellectual disability, or cluster b personality disorder (e.g., borderline personality
        disorder, antisocial personality disorder, histrionic personality disorder, and
        narcissistic personality disorder) -Participant has a current or prior DSM-IV-TR diagnosis
        of a psychotic disorder, MDD with psychosis, post-traumatic stress disorder (PTSD), or
        obsessive compulsive disorder (OCD) -Anatomical or medical conditions that may impede
        delivery or absorption of study medication (e.g., undergone facial reconstruction,
        rhinoplasty, significant structural or functional abnormalities of the nose or upper
        airway; obstructions or mucosal lesions of the nostrils or nasal passages; undergone sinus
        surgery in the previous 2 years; signs and symptoms of rhinitis) -Has an abnormal or
        deviated nasal septum with any 1 or more of the following symptoms: blockage of 1 or both
        nostrils, nasal congestion (especially 1-sided), frequent nosebleeds, frequent sinus
        infections, and at times has facial pain, headaches, and postnasal drip -Has a history of
        substance abuse (drug or alcohol) or dependence (except nicotine or caffeine) within the
        previous 1 year of the screening visit -Participant has known allergies, hypersensitivity,
        intolerance, or contraindication to esketamine/ketamine or its excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lede</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ichikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanzaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kodaira</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibukawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&amp;amp;parentIdentifier=CR102968&amp;amp;attachmentIdentifier=71cc4b21-a4b5-44af-8c9b-04d0131f96f4&amp;amp;fileName=ESKETINTRD2003_(CR102968)_Additional_results_data_CH.pdf&amp;amp;versionIdentifier=</url>
    <description>A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>May 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2019</results_first_posted>
  <disposition_first_submitted>April 20, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 20, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 19, 2016</disposition_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment resistant depressive disorder</keyword>
  <keyword>Intranasal esketamine</keyword>
  <keyword>Efficacy</keyword>
  <keyword>SYNAPSE</keyword>
  <keyword>JNJ-54135419</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Panel A: Period 1)</title>
          <description>Participants self-administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="P2">
          <title>Esketamine 28 mg (Panel A: Period 1)</title>
          <description>Participants self administered esketamine 28 milligram (mg) intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="P3">
          <title>Esketamine 56 mg (Panel A: Period 1)</title>
          <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="P4">
          <title>Esketamine 84 mg (Panel A: Period 1)</title>
          <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="P5">
          <title>Placebo (Panel B: Period 1)</title>
          <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1 in Panel B.</description>
        </group>
        <group group_id="P6">
          <title>Esketamine 14 mg (Panel B: Period 1)</title>
          <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1 in Panel B.</description>
        </group>
        <group group_id="P7">
          <title>Esketamine 56 mg (Panel B: Period 1)</title>
          <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1 in Panel B.</description>
        </group>
        <group group_id="P8">
          <title>Placebo (Panel A: Period 2) QIDS &gt;= 11 Participants</title>
          <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score greater than or equal to [&gt;=] 11) were re-randomized to receive Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
        </group>
        <group group_id="P9">
          <title>Placebo (Panel A: Period 2) QIDS&lt;11 Participants</title>
          <description>Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel A continued to receive placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
        </group>
        <group group_id="P10">
          <title>Placebo to Esketamine 28mg (Panel A: Period 2)</title>
          <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were re-randomized to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
        </group>
        <group group_id="P11">
          <title>Placebo to Esketamine 56 mg (Panel A: Period 2)</title>
          <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were re-randomized to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
        </group>
        <group group_id="P12">
          <title>Placebo to Esketamine 84 mg (Panel A: Period 2)</title>
          <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were re-randomized to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
        </group>
        <group group_id="P13">
          <title>Esketamine 28 mg (Panel A: Period 2)</title>
          <description>Participants who received esketamine 28 mg in Period 1 of Panel A continued to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
        </group>
        <group group_id="P14">
          <title>Esketamine 56 mg (Panel A: Period 2)</title>
          <description>Participants who received esketamine 56 mg in Period 1 of Panel A continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
        </group>
        <group group_id="P15">
          <title>Esketamine 84 mg (Panel A: Period 2)</title>
          <description>Participants who received esketamine 84 mg in Period 1 of Panel A continued to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
        </group>
        <group group_id="P16">
          <title>Placebo (Panel B: Period 2) QIDS &gt;=11 Participants</title>
          <description>Participants who were non-responders with QIDS-SR16 score &gt;=11 at the end of Period 1 were re-randomized to receive placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes using 4 separate devices) on Days 8 and 11 of Period 2 in Panel B.</description>
        </group>
        <group group_id="P17">
          <title>Placebo (Panel B: Period 2) QIDS&lt;11 Participants</title>
          <description>Participants who were responders with QIDS-SR16 score &lt;11 at the end of Period 1 continued to receive placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes using 4 separate devices) on Days 8 and 11 in Period 2.</description>
        </group>
        <group group_id="P18">
          <title>Placebo to Esketamine 14mg (Panel B: Period 2)</title>
          <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 at the end of Period 1 were re-randomized to receive esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo in other nostril at 0 minute and 1 spray of placebo in each nostril at 5 minutes using 4 separate devices) on Days 8 and 11 in Period 2.</description>
        </group>
        <group group_id="P19">
          <title>Placebo to Esketamine 56mg (Panel B: Period 2)</title>
          <description>Participants who received placebo in Period 1 and were non-responders (with QIDS-SR16 score &gt;=11) at the end of Period 1 in Panel B were re-randomized to receive esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
        </group>
        <group group_id="P20">
          <title>Esketamine 14 mg (Panel B: Period 2)</title>
          <description>Participants who received esketamine 14 mg in Period 1 of Panel B continued to receive esketamine 14 mg (1 spray of esketamine 14 mg to one nostril and 1 spray of placebo into other nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 in Period 2.</description>
        </group>
        <group group_id="P21">
          <title>Esketamine 56 mg (Panel B: Period 2)</title>
          <description>Participants who received esketamine 56 mg in Period 1 of Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
        </group>
        <group group_id="P22">
          <title>Placebo/Placebo/Open Label Esketamine (Panel A)</title>
          <description>Participants who received Placebo in Period 1 and 2 of Panel A and elected to continue with open label phase received up to 9 single doses of intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60 and 74. The doses for the optional open-label treatment phase included 28, 56, and 84 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22, 25, 32, 39, and 46 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment. The same dose administered on Day 46 was administered on Day 60 and Day 74.</description>
        </group>
        <group group_id="P23">
          <title>Placebo/Esketamine/Open Label Esketamine (Panel A)</title>
          <description>Participants who received Placebo in Period 1 and esketamine in Period 2 of Panel A and elected to continue with open label phase received up to 9 single doses of intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60 and 74. The doses for the optional open-label treatment phase included 28, 56, and 84 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22, 25, 32, 39, and 46 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment. The same dose administered on Day 46 was administered on Day 60 and Day 74.</description>
        </group>
        <group group_id="P24">
          <title>Esketamine/Esketamine/Open Label Esketamine (Panel A)</title>
          <description>Participants who received esketamine in Period 1 and 2 of Panel A and elected to continue with open label phase received up to 9 single doses of intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60 and 74. The doses for the optional open-label treatment phase included 28, 56, and 84 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22, 25, 32, 39, and 46 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment. The same dose administered on Day 46 was administered on Day 60 and Day 74.</description>
        </group>
        <group group_id="P25">
          <title>Placebo/Placebo/Open Label Esketamine (Panel B)</title>
          <description>Participants who received Placebo in Period 1 and 2 of Panel A and elected to continue with open label phase received up to 4 single doses of intranasal esketamine on Days 15, 18, 22 and 25. The doses for the optional open-label treatment phase included 14, 28 and 56 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22 and 25 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment.</description>
        </group>
        <group group_id="P26">
          <title>Placebo/Esketamine/Open Label Esketamine (Panel B)</title>
          <description>Participants who received Placebo in Period 1 and esketamine in Period 2 of Panel A and elected to continue with open label phase received up to 4 single doses of intranasal esketamine on Days 15, 18, 22 and 25. The doses for the optional open-label treatment phase included 14, 28 and 56 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22 and 25 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment.</description>
        </group>
        <group group_id="P27">
          <title>Esketamine/Esketamine/Open Label Esketamine (Panel B)</title>
          <description>Participants who received esketamine in Period 1 and 2 of Panel A and elected to continue with open label phase received up to 4 single doses of intranasal esketamine on Days 15, 18, 22 and 25. The doses for the optional open-label treatment phase included 14, 28 and 56 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22 and 25 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment.</description>
        </group>
        <group group_id="P28">
          <title>Placebo: Follow up Phase</title>
          <description>All participants whose last dose was Placebo in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="P29">
          <title>Esketamine 14 mg: Follow up Phase</title>
          <description>All participants whose last dose was esketamine 14 mg in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="P30">
          <title>Esketamine 28 mg: Follow up Phase</title>
          <description>All participants whose last dose was esketamine 28 mg in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="P31">
          <title>Esketamine 56 mg: Follow up Phase</title>
          <description>All participants whose last dose was esketamine 56 mg in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="P32">
          <title>Esketamine 84 mg: Follow up Phase</title>
          <description>All participants whose last dose was esketamine 84 mg in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Panel A and B)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rerandomized to Esketamine 56 mg</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rerandomized to Esketamine 28mg</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rerandomized to Esketamine 84mg</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (Panel A and B)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="11"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="5"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="3"/>
                <participants group_id="P20" count="11"/>
                <participants group_id="P21" count="9"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="11"/>
                <participants group_id="P15" count="10"/>
                <participants group_id="P16" count="5"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="5"/>
                <participants group_id="P19" count="2"/>
                <participants group_id="P20" count="11"/>
                <participants group_id="P21" count="9"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Phase (Optional)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="10"/>
                <participants group_id="P23" count="20"/>
                <participants group_id="P24" count="27"/>
                <participants group_id="P25" count="13"/>
                <participants group_id="P26" count="7"/>
                <participants group_id="P27" count="19"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="7"/>
                <participants group_id="P23" count="11"/>
                <participants group_id="P24" count="23"/>
                <participants group_id="P25" count="13"/>
                <participants group_id="P26" count="7"/>
                <participants group_id="P27" count="19"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="3"/>
                <participants group_id="P23" count="9"/>
                <participants group_id="P24" count="4"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="1"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="5"/>
                <participants group_id="P24" count="1"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="1"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="1"/>
                <participants group_id="P23" count="2"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="2"/>
                <participants group_id="P23" count="1"/>
                <participants group_id="P24" count="2"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="1"/>
                <participants group_id="P29" count="4"/>
                <participants group_id="P30" count="12"/>
                <participants group_id="P31" count="39"/>
                <participants group_id="P32" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="1"/>
                <participants group_id="P29" count="4"/>
                <participants group_id="P30" count="12"/>
                <participants group_id="P31" count="39"/>
                <participants group_id="P32" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
                <participants group_id="P28" count="0"/>
                <participants group_id="P29" count="0"/>
                <participants group_id="P30" count="0"/>
                <participants group_id="P31" count="0"/>
                <participants group_id="P32" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Panel A: Period 1)</title>
          <description>Participants self-administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="B2">
          <title>Esketamine 28 mg (Panel A: Period 1)</title>
          <description>Participants self administered esketamine 28 milligram (mg) intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="B3">
          <title>Esketamine 56 mg (Panel A: Period 1)</title>
          <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="B4">
          <title>Esketamine 84 mg (Panel A: Period 1)</title>
          <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="B5">
          <title>Placebo (Panel B: Period 1)</title>
          <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1 in Panel B.</description>
        </group>
        <group group_id="B6">
          <title>Esketamine 14 mg (Panel B: Period 1)</title>
          <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1 in Panel B.</description>
        </group>
        <group group_id="B7">
          <title>Esketamine 56 mg (Panel B: Period 1)</title>
          <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1 in Panel B.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="21"/>
            <count group_id="B6" value="11"/>
            <count group_id="B7" value="9"/>
            <count group_id="B8" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="9.60"/>
                    <measurement group_id="B2" value="42.1" spread="10.31"/>
                    <measurement group_id="B3" value="42.7" spread="11.23"/>
                    <measurement group_id="B4" value="49.8" spread="9.29"/>
                    <measurement group_id="B5" value="45.3" spread="7.66"/>
                    <measurement group_id="B6" value="42.2" spread="9.43"/>
                    <measurement group_id="B7" value="45.6" spread="7.35"/>
                    <measurement group_id="B8" value="44.6" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Panel A and B: Change From Baseline (Day 1) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Day 8- Analysis of Covariance (ANCOVA) Analysis</title>
        <description>MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
        <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
        <population>Period 1 Intent-to-treat (ITT) analysis set included all participants randomly assigned to treatment in period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 1 Esketamine 28 mg</title>
            <description>Participants self administered esketamine 28 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 1 Esketamine 84 mg</title>
            <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 1 Esketamine 14 mg</title>
            <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 1) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Day 8- Analysis of Covariance (ANCOVA) Analysis</title>
          <description>MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
          <population>Period 1 Intent-to-treat (ITT) analysis set included all participants randomly assigned to treatment in period 1.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="1.74"/>
                    <measurement group_id="O2" value="-9.8" spread="2.72"/>
                    <measurement group_id="O3" value="-12.4" spread="2.66"/>
                    <measurement group_id="O4" value="-15.3" spread="2.56"/>
                    <measurement group_id="O5" value="-6.6" spread="1.53"/>
                    <measurement group_id="O6" value="-4.8" spread="2.13"/>
                    <measurement group_id="O7" value="-10.3" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Panel A and B: Change From Baseline (Day 8) in Montgomery Asberg Depression Rating Scale Total Score at Day 15- ANCOVA Analysis</title>
        <description>MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
        <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
        <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 2 Placebo</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with Quick Inventory of Depressive Symptomatology – 16-item Self Report (QIDS-SR16) score &gt;=11) were randomly re-assigned to receive same Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel A:Period 2 Esketamine 28 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 2 Esketamine 56 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly re-assigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 2 Esketamine 84 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 2 Placebo</title>
            <description>Participants who were non-responders with QIDS-SR 16 score &gt;=11 received placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 2 Esketamine 14 mg</title>
            <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 received esketamine 14 mg intranasally (1 spray of esketamine into one nostril and 1 spray of placebo in other nostril at 0 minutes and 1 spray of placebo in each nostril at 5 minutes) in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>Panel B:Period 2 Esketamine 56 mg</title>
            <description>Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 8) in Montgomery Asberg Depression Rating Scale Total Score at Day 15- ANCOVA Analysis</title>
          <description>MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
          <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="2.92"/>
                    <measurement group_id="O2" value="-7.6" spread="2.49"/>
                    <measurement group_id="O3" value="-8.9" spread="2.51"/>
                    <measurement group_id="O4" value="-11.4" spread="2.68"/>
                    <measurement group_id="O5" value="-0.7" spread="3.32"/>
                    <measurement group_id="O6" value="-6.6" spread="4.02"/>
                    <measurement group_id="O7" value="-1.2" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Have Completed the Double-Blind Phase and Received the Same Treatment for Both Periods</title>
        <description>Sustained response was defined as at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
        <time_frame>Day 2 Up to Day 15</time_frame>
        <population>Population analyzed included participants from double-blind (DB) ITT (who were randomly assigned to treatment during the double-blind phase) who completed the double-blind phase and received the same treatment for both periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Placebo (Period 1 and 2)</title>
            <description>Participants who received same placebo (1 spray to each nostril at 0, 5 and 10 minutes) treatment in Period 1 and 2 of Panel A.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Esketamine 28 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 28mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) treatment in Period 1 and 2 of Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Esketamine 56 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) treatment in Period 1 and 2 of Panel A.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Esketamine 84 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) treatment in Period 1 and 2 of Panel A.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Placebo (Period 1 and 2)</title>
            <description>Participants who received same placebo (1 spray to each nostril at 0 and 5 minutes) treatment in Period 1 and 2 of Panel B.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Esketamine 14 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 14 mg (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) treatment in Period 1 and 2 of Panel B.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Esketamine 56 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 56 mg (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) treatment in Period 1 and 2 of Panel B.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Have Completed the Double-Blind Phase and Received the Same Treatment for Both Periods</title>
          <description>Sustained response was defined as at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
          <population>Population analyzed included participants from double-blind (DB) ITT (who were randomly assigned to treatment during the double-blind phase) who completed the double-blind phase and received the same treatment for both periods.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="30.0"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="18.2"/>
                    <measurement group_id="O7" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Received the Same Treatment for Both Periods, Including Participants Who Did Not Complete the Double-blind Phase</title>
        <description>Sustained response was defined as at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
        <time_frame>Day 2 Up to Day 15</time_frame>
        <population>Population analyzed included participants from DB ITT (who were randomly assigned to treatment during the double-blind phase) who received the same treatment for both periods, including participants who did not complete the double-blind Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Placebo (Period 1 and 2)</title>
            <description>Participants who received same placebo (1 spray to each nostril at 0, 5 and 10 minutes) treatment in Period 1 and 2 of Panel A.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Esketamine 28 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 28mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) treatment in Period 1 and 2 of Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Esketamine 56 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) treatment in Period 1 and 2 of Panel A.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Esketamine 84 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) treatment in Period 1 and 2 of Panel A.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Placebo (Period 1 and 2)</title>
            <description>Participants who received same placebo (1 spray to each nostril at 0 and 5 minutes) treatment in Period 1 and 2 of Panel B.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Esketamine 14 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 14 mg (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) treatment in Period 1 and 2 of Panel B.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Esketamine 56 mg (Period 1 and 2)</title>
            <description>Participants who received same esketamine 56 mg (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) treatment in Period 1 and 2 of Panel B.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Received the Same Treatment for Both Periods, Including Participants Who Did Not Complete the Double-blind Phase</title>
          <description>Sustained response was defined as at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
          <population>Population analyzed included participants from DB ITT (who were randomly assigned to treatment during the double-blind phase) who received the same treatment for both periods, including participants who did not complete the double-blind Phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="18.2"/>
                    <measurement group_id="O7" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Percentage of Participants With Response Based on MADRS Total Score</title>
        <description>A participant is defined a responder at a given time point if the percent improvement in MADRS is greater than or equal to (&gt;=) 50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
        <time_frame>Period 1: Days 1 (2 hour), 2 and 8 of Double-blind Phase</time_frame>
        <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 1 Esketamine 28 mg</title>
            <description>Participants self administered esketamine 28 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 1 Esketamine 84 mg</title>
            <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 1 Esketamine 14 mg</title>
            <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Percentage of Participants With Response Based on MADRS Total Score</title>
          <description>A participant is defined a responder at a given time point if the percent improvement in MADRS is greater than or equal to (&gt;=) 50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
          <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (2 hour)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="36.4"/>
                    <measurement group_id="O4" value="58.3"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="36.4"/>
                    <measurement group_id="O7" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="27.3"/>
                    <measurement group_id="O4" value="41.7"/>
                    <measurement group_id="O5" value="28.6"/>
                    <measurement group_id="O6" value="36.4"/>
                    <measurement group_id="O7" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="41.7"/>
                    <measurement group_id="O5" value="23.8"/>
                    <measurement group_id="O6" value="18.2"/>
                    <measurement group_id="O7" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Percentage of Participants With Response Based on MADRS Total Score</title>
        <description>A participant is defined a responder at a given time point if the percent improvement in MADRS is &gt;=50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
        <time_frame>Period 2: Days 1 (2 hour), 2 and 8 of Double-blind Phase</time_frame>
        <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 2 Placebo</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with Quick Inventory of Depressive Symptomatology – 16-item Self Report (QIDS-SR16) score &gt;=11) were randomly re-assigned to receive same Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 2 Esketamine 28 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 2 Esketamine 56 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly re-assigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 2 Esketamine 84 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 2 Placebo</title>
            <description>Participants who were non-responders with QIDS-SR 16 score &gt;=11 received placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 2 Esketamine 14 mg</title>
            <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 received esketamine 14 mg intranasally (1 spray of esketamine into one nostril and 1 spray of placebo in other nostril at 0 minutes and 1 spray of placebo in each nostril at 5 minutes) in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 2 Esketamine 56 mg</title>
            <description>Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Percentage of Participants With Response Based on MADRS Total Score</title>
          <description>A participant is defined a responder at a given time point if the percent improvement in MADRS is &gt;=50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
          <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (2 hour)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="40.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="60.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="40.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="80.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="20.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Percentage of Participants in Remission Based on MADRS Total Score at Days 1, 2 and 8 of Double-blind Phase</title>
        <description>Participants who had a MADRS total score of &lt;=10 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
        <time_frame>Days 1, 2 and 8 of Double-blind Phase of Period 1</time_frame>
        <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 1: Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 1 Esketamine 28 mg</title>
            <description>Participants self administered esketamine 28 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 1: Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 1 Esketamine 84 mg</title>
            <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 1 Esketamine 14 mg</title>
            <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Percentage of Participants in Remission Based on MADRS Total Score at Days 1, 2 and 8 of Double-blind Phase</title>
          <description>Participants who had a MADRS total score of &lt;=10 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.</description>
          <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="19.0"/>
                    <measurement group_id="O6" value="36.4"/>
                    <measurement group_id="O7" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="19.0"/>
                    <measurement group_id="O6" value="27.3"/>
                    <measurement group_id="O7" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O6" value="18.2"/>
                    <measurement group_id="O7" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Percentage of Participants in Remission Based on MADRS Total Score at Days 1, 2 and 8 of Double-blind Phase</title>
        <description>Participants who had a MADRS total score of less than or equal to (&lt;=10) were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
        <time_frame>Days 1, 2 and 8 of Double-blind Phase of Period 2</time_frame>
        <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 2 Placebo</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with Quick Inventory of Depressive Symptomatology – 16-item Self Report (QIDS-SR16) score &gt;=11) were randomly re-assigned to receive same Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 2 Esketamine 28 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 2 Esketamine 56 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly re-assigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 2 Esketamine 84 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 2 Placebo</title>
            <description>Participants who were non-responders with QIDS-SR 16 score &gt;=11 received placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 2 Esketamine 14 mg</title>
            <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 received esketamine 14 mg intranasally (1 spray of esketamine into one nostril and 1 spray of placebo in other nostril at 0 minutes and 1 spray of placebo in each nostril at 5 minutes) in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 2 Esketamine 56 mg</title>
            <description>Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Percentage of Participants in Remission Based on MADRS Total Score at Days 1, 2 and 8 of Double-blind Phase</title>
          <description>Participants who had a MADRS total score of less than or equal to (&lt;=10) were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.</description>
          <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="40.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="60.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="20.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="80.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="20.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Change From Baseline (Day 1) in Quick Inventory of Depressive Symptomatology-16-item Self Report (QIDS-SR16) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis</title>
        <description>QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.</description>
        <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
        <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 1 Esketamine 28 mg</title>
            <description>Participants self administered esketamine 28 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 1 Esketamine 84 mg</title>
            <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 1 Esketamine 14 mg</title>
            <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 1) in Quick Inventory of Depressive Symptomatology-16-item Self Report (QIDS-SR16) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis</title>
          <description>QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.</description>
          <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.93"/>
                    <measurement group_id="O2" value="-4.0" spread="1.43"/>
                    <measurement group_id="O3" value="-4.4" spread="1.43"/>
                    <measurement group_id="O4" value="-4.2" spread="1.39"/>
                    <measurement group_id="O5" value="-1.1" spread="0.78"/>
                    <measurement group_id="O6" value="-0.6" spread="1.10"/>
                    <measurement group_id="O7" value="-3.0" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Change From Baseline (Day 8) in Quick Inventory of Depressive Symptomatology-16-item Self Report Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis</title>
        <description>QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.</description>
        <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
        <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 2 Placebo</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with Quick Inventory of Depressive Symptomatology – 16-item Self Report (QIDS-SR16) score &gt;=11) were randomly re-assigned to receive same Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 2 Esketamine 28 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 2 Esketamine 56 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly re-assigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 2 Esketamine 84 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 2 Placebo</title>
            <description>Participants who were non-responders with QIDS-SR 16 score &gt;=11 received placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 2 Esketamine 14 mg</title>
            <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 received esketamine 14 mg intranasally (1 spray of esketamine into one nostril and 1 spray of placebo in other nostril at 0 minutes and 1 spray of placebo in each nostril at 5 minutes) in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 2 Esketamine 56 mg</title>
            <description>Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 8) in Quick Inventory of Depressive Symptomatology-16-item Self Report Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis</title>
          <description>QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.</description>
          <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.50"/>
                    <measurement group_id="O2" value="-3.1" spread="1.35"/>
                    <measurement group_id="O3" value="-2.0" spread="1.41"/>
                    <measurement group_id="O4" value="-3.3" spread="1.48"/>
                    <measurement group_id="O5" value="-2.1" spread="1.78"/>
                    <measurement group_id="O6" value="-5.7" spread="1.78"/>
                    <measurement group_id="O7" value="-1.5" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Change From Baseline (Day 1) in Clinical Global Impression - Severity (CGI-S) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</title>
        <description>CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.</description>
        <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
        <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 1 Esketamine 28 mg</title>
            <description>Participants self administered esketamine 28 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 1 Esketamine 84 mg</title>
            <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 1 Esketamine 14 mg</title>
            <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 1) in Clinical Global Impression - Severity (CGI-S) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</title>
          <description>CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.</description>
          <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O4" value="4.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O5" value="4.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O6" value="4.0" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O7" value="3.0" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Change From Baseline (Day 8) in Clinical Global Impression - Severity Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</title>
        <description>CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.</description>
        <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
        <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 2 Placebo</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with Quick Inventory of Depressive Symptomatology – 16-item Self Report (QIDS-SR16) score &gt;=11) were randomly re-assigned to receive same Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 2 Esketamine 28 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 2 Esketamine 56 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly re-assigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 2 Esketamine 84 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 2 Placebo</title>
            <description>Participants who were non-responders with QIDS-SR 16 score &gt;=11 received placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 2 Esketamine 14 mg</title>
            <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 received esketamine 14 mg intranasally (1 spray of esketamine into one nostril and 1 spray of placebo in other nostril at 0 minutes and 1 spray of placebo in each nostril at 5 minutes) in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 2 Esketamine 56 mg</title>
            <description>Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 8) in Clinical Global Impression - Severity Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</title>
          <description>CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.</description>
          <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O3" value="5.0" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O4" value="4.0" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O5" value="4.0" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O6" value="3.0" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="O7" value="4.0" lower_limit="4" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Change From Baseline (Day 1) in Generalized Anxiety Disorder (GAD-7) Total Score at Day 8 (Double-Blind Treatment Phase) ANCOVA Analysis</title>
        <description>GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).</description>
        <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
        <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 1 Esketamine 28 mg</title>
            <description>Participants self administered esketamine 28 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 1 Esketamine 84 mg</title>
            <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 1 Esketamine 14 mg</title>
            <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 1) in Generalized Anxiety Disorder (GAD-7) Total Score at Day 8 (Double-Blind Treatment Phase) ANCOVA Analysis</title>
          <description>GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).</description>
          <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.88"/>
                    <measurement group_id="O2" value="-1.5" spread="1.34"/>
                    <measurement group_id="O3" value="-3.1" spread="1.34"/>
                    <measurement group_id="O4" value="-5.1" spread="1.30"/>
                    <measurement group_id="O5" value="-1.7" spread="0.68"/>
                    <measurement group_id="O6" value="-1.9" spread="0.94"/>
                    <measurement group_id="O7" value="-3.2" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Change From Baseline (Day 8) in Generalized Anxiety Disorder-7 Total Score at Day 15 (Double-Blind Treatment Phase)- ANCOVA Analysis</title>
        <description>GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).</description>
        <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
        <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 2 Placebo</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with Quick Inventory of Depressive Symptomatology – 16-item Self Report (QIDS-SR16) score &gt;=11) were randomly re-assigned to receive same Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 2 Esketamine 28 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 2 Esketamine 56 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly re-assigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 2 Esketamine 84 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 2 Placebo</title>
            <description>Participants who were non-responders with QIDS-SR 16 score &gt;=11 received placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 2 Esketamine 14 mg</title>
            <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 received esketamine 14 mg intranasally (1 spray of esketamine into one nostril and 1 spray of placebo in other nostril at 0 minutes and 1 spray of placebo in each nostril at 5 minutes) in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 2 Esketamine 56 mg</title>
            <description>Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 8) in Generalized Anxiety Disorder-7 Total Score at Day 15 (Double-Blind Treatment Phase)- ANCOVA Analysis</title>
          <description>GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).</description>
          <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.02"/>
                    <measurement group_id="O2" value="-1.6" spread="0.87"/>
                    <measurement group_id="O3" value="1.0" spread="0.98"/>
                    <measurement group_id="O4" value="-0.9" spread="1.02"/>
                    <measurement group_id="O5" value="-2.7" spread="1.68"/>
                    <measurement group_id="O6" value="-6.6" spread="1.68"/>
                    <measurement group_id="O7" value="-0.7" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Change From Baseline (Day 1) in Patient Global Impression of Severity (PGI-S) Score Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</title>
        <description>PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition.</description>
        <time_frame>Baseline (Day 1) and Endpoint (Day 8) of Period 1</time_frame>
        <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 1 Esketamine 28 mg</title>
            <description>Participants self administered esketamine 28 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 1 Esketamine 84 mg</title>
            <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 1 Placebo</title>
            <description>Participants self administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 1 Esketamine 14 mg</title>
            <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 1 Esketamine 56 mg</title>
            <description>Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 1) in Patient Global Impression of Severity (PGI-S) Score Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</title>
          <description>PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition.</description>
          <population>Period 1 ITT analysis set included all participants randomly assigned to treatment in period 1.</population>
          <units>Unit on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O5" value="3.0" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O6" value="3.0" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O7" value="3.0" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Panel A and B: Change From Baseline (Day 8) in Patient Global Impression of Severity Score Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</title>
        <description>PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. A negative change in score indicates improvement.</description>
        <time_frame>Baseline (Day 8) and Endpoint (Day 15) of Period 2</time_frame>
        <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: Period 2 Placebo</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with Quick Inventory of Depressive Symptomatology – 16-item Self Report (QIDS-SR16) score &gt;=11) were randomly re-assigned to receive same Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Panel A: Period 2 Esketamine 28 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Panel A: Period 2 Esketamine 56 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly re-assigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O4">
            <title>Panel A: Period 2 Esketamine 84 mg</title>
            <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR 16 score &gt;=11) were randomly re-assigned to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Panel B: Period 2 Placebo</title>
            <description>Participants who were non-responders with QIDS-SR 16 score &gt;=11 received placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes) on Days 8 and 11 of Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Panel B: Period 2 Esketamine 14 mg</title>
            <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 received esketamine 14 mg intranasally (1 spray of esketamine into one nostril and 1 spray of placebo in other nostril at 0 minutes and 1 spray of placebo in each nostril at 5 minutes) in Period 2.</description>
          </group>
          <group group_id="O7">
            <title>Panel B: Period 2 Esketamine 56 mg</title>
            <description>Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Panel A and B: Change From Baseline (Day 8) in Patient Global Impression of Severity Score Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks</title>
          <description>PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. A negative change in score indicates improvement.</description>
          <population>Period 2 ITT analysis set included non-responders (QIDS-SR16 total score &gt;=11) to placebo treatment in Period 1 and were then randomly re-assigned to a treatment group in Period 2. Only placebo participants with a QIDS-SR16 score &gt;= 11 at End Point Period 1 who were re-randomized in Period 2 are included in the Period 2 summary.</population>
          <units>Unit on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O3" value="4.0" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O4" value="3.0" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O5" value="3.0" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O6" value="3.0" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O7" value="3.0" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 21 weeks</time_frame>
      <desc>Safety analysis set for double-blind and open-label phase included all randomized participants who receive at least 1 dose of study drug in the respective phases. For follow-up phase safety population included all participants who entered in follow up phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Panel A and B: Period 1)</title>
          <description>Panel A: Participants self-administered placebo intranasally (1 spray to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A. Panel B: Participants self-administered placebo intranasally (1 spray to each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1 in Panel B.</description>
        </group>
        <group group_id="E2">
          <title>Esketamine 28 mg (Panel A: Period 1)</title>
          <description>Participants self administered esketamine 28 milligram (mg) intranasally (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Panel A and B: Period 2) QIDS &gt;=11 Participants</title>
          <description>Panel A: Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly reassigned to receive same Placebo (1 spray to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2 in Panel A. Panel B: Participants who were non-responders with QIDS-SR16 score &gt;=11 at the end of Period 1 were randomly assigned to receive placebo intranasally (1 spray of placebo into each nostril at 0 and 5 minutes using 4 separate devices) on Days 8 and 11 of Period 2 in Panel B.</description>
        </group>
        <group group_id="E4">
          <title>Placebo to Esketamine 14mg (Panel B: Period 2)</title>
          <description>Participants who received placebo in Period 1 and were non-responders with QIDS-SR16 score &gt;=11 at the end of Period 1 were randomly reassigned to receive esketamine 14 mg intranasally (1 spray of esketamine 14 mg into once nostril and 1 spray of placebo in other nostril at 0 minute and 1 spray of placebo in each nostril at 5 minutes using 4 separate devices) on Days 8 and 11 in Period 2 of Panel B.</description>
        </group>
        <group group_id="E5">
          <title>Placebo to Esketamine 28mg (Panel A: Period 2)</title>
          <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly reassigned to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2 in Panel A.</description>
        </group>
        <group group_id="E6">
          <title>Placebo to Esketamine 56mg (Panel A and B: Period 2)</title>
          <description>Panel A: Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly reassigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2 in Panel A. Panel B: Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2 of Panel B.</description>
        </group>
        <group group_id="E7">
          <title>Placebo to Esketamine 84 mg (Panel A: Period 2)</title>
          <description>Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly reassigned to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2 in Panel A.</description>
        </group>
        <group group_id="E8">
          <title>Placebo (Panel A and Panel B: Period 2)</title>
          <description>All participants who received placebo in Period 2 of Panel A and B (including participants with QIDS-SR16 score &gt;=11 and QIDS-SR16 score &lt;11) in double-blind phase.</description>
        </group>
        <group group_id="E9">
          <title>Esketamine 14 mg (Panel B: Period 2)</title>
          <description>Participants who received esketamine 14 mg in Period 1 of Panel B continued to receive esketamine 14 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2 of Panel B.</description>
        </group>
        <group group_id="E10">
          <title>Esketamine 28 mg (Panel A: Period 2)</title>
          <description>Participants who received esketamine 28 mg in Period 1 of Panel A continued to receive esketamine 28 mg (1 spray of esketamine 14 mg to each nostril at 0 minute and 1 spray of placebo to each nostril at 5 and 10 minutes) on Days 8 and 11 of Period 2 in Panel A.</description>
        </group>
        <group group_id="E11">
          <title>Esketamine 56 mg (Panel A and B: Period 2)</title>
          <description>Panel A: Participants who were non-responders at the end of Period 1 in Panel A (with QIDS-SR16 score &gt;=11) were randomly re-assigned to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 of Period 2. Panel B: Participants who were responders (with QIDS-SR16 score &lt;11) at the end of Period 1 in Panel B continued to receive esketamine 56 mg (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 8 and 11 in Period 2.</description>
        </group>
        <group group_id="E12">
          <title>Placebo/Placebo/Open Label Esketamine (Panel A and B)</title>
          <description>Panel A: Participants who received Placebo in Period 1 and 2 of Panel A and elected to continue with open label (OL) phase received up to 9 single doses of intranasal esketamine on Days 15,18,22,25,32, 39, 46,60,74. Doses for optional OL phase included 28, 56, and 84 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18,22,25,32,39,46 could be adjusted to next lower or higher dose, based on investigator’s clinical judgment. Same dose administered on Day 46 was administered on Day 60, 74. Panel B: Participants who received Placebo in Period 1 and 2 of Panel A and elected to continue with OL phase received up to 4 single doses of intranasal esketamine on Days 15, 18, 22, 25. Doses for OL phase included 14, 28, 56 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22, 25 could be adjusted to next lower or higher dose, based on investigator’s clinical judgment.</description>
        </group>
        <group group_id="E13">
          <title>Placebo/Esketamine/Open Label Esketamine (Panel A and B)</title>
          <description>Panel A: Participants who received Placebo in Period 1, esketamine in Period 2 and elected to continue with OL phase received up to 9 single doses of intranasal esketamine on Days 15,18,22,25,32,39,46,60, 74. Doses for OL phase included 28,56,84 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18,22,25,32,39, 46 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment. Same dose administered on Day 46 was administered on Day 60,74. Panel B: Participants who received Placebo in Period 1 and esketamine in Period 2 of Panel A and elected to continue with OL phase received up to 4 single doses of intranasal esketamine on Days 15,18,22,25. Doses for OL phase included 14,28,56 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18,22,25 could be adjusted to next lower or higher dose, based on the investigator’s clinical judgment.</description>
        </group>
        <group group_id="E14">
          <title>Esketamine/Esketamine/Open Label Esketamine (Panel A and B)</title>
          <description>Panel A: Participants who received esketamine in Period 1 and 2 and elected to continue with open label phase received up to 9 single doses of intranasal esketamine on Days 15,18,22,25,32,39,46,60,74. Doses for OL treatment phase included 28, 56, 84 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22,25,32,39, 46 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment. Same dose administered on Day 46 was administered on Day 60,74.Panel B: Participants who received esketamine in Period 1 and 2 of Panel A and elected to continue with OL phase received up to 4 single doses of intranasal esketamine on Days 15, 18, 22, 25. Doses for OL phase included 14, 28, 56 mg of esketamine. All participants started with intranasal esketamine 56 mg on Day 15. Subsequent doses on Days 18, 22, 25 could be adjusted to the next lower or higher dose, based on the investigator’s clinical judgment.</description>
        </group>
        <group group_id="E15">
          <title>Placebo: Follow up Phase</title>
          <description>All participants whose last dose was Placebo in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="E16">
          <title>Esketamine 14 mg: Follow up Phase</title>
          <description>All participants whose last dose was esketamine 14 mg in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="E17">
          <title>Esketamine 28 mg: Follow up Phase</title>
          <description>All participants whose last dose was esketamine 28 mg in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="E18">
          <title>Esketamine 56 mg: Follow up Phase</title>
          <description>All participants whose last dose was esketamine 56 mg in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="E19">
          <title>Esketamine 84 mg: Follow up Phase</title>
          <description>All participants whose last dose was esketamine 84 mg in the double-blind phase or open label phase and were not consent withdrawn were followed for safety for 8 weeks.</description>
        </group>
        <group group_id="E20">
          <title>Esketamine 14 mg (Panel B: Period 1)</title>
          <description>Participants self administered esketamine 14 mg intranasally (1 spray of esketamine 14 mg into one nostril and 1 spray of placebo into other nostril at 0 minute and then 1 spray of placebo to each nostril at 5 minutes) on Days 1 and 4 of Period 1 in Panel B.</description>
        </group>
        <group group_id="E21">
          <title>Esketamine 56 mg (Panel A and B: Period 1)</title>
          <description>Panel A: Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0 and 5 minute and 1 spray of placebo to each nostril at 10 minutes) on Days 1 and 4 of Period 1. Panel B: Participants self administered esketamine 56 mg intranasally (1 spray of esketamine 14 mg into each nostril at 0 and 5 minutes) on Days 1 and 4 of Period 1.</description>
        </group>
        <group group_id="E22">
          <title>Esketamine 84 mg (Panel A: Period 1)</title>
          <description>Participants self administered esketamine 84 mg intranasally (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 1 and 4 of Period 1 in Panel A.</description>
        </group>
        <group group_id="E23">
          <title>Esketamine 84 mg (Panel A: Period 2)</title>
          <description>Participants who received esketamine 84 mg in Period 1 of Panel A continued to receive esketamine 84 mg (1 spray of esketamine 14 mg to each nostril at 0, 5 and 10 minutes) on Days 8 and 11 of Period 2 in Panel A.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="26" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="22" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="39" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="12" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Accommodation Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oral Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Paraesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Salivary Hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Erosive Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oesophageal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Energy Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Feeling Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Feeling Drunk</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Feeling Jittery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Injection Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Product Taste Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sluggishness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin Abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Diastolic Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood Pressure Systolic Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oxygen Saturation Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>C-Reactive Protein Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Limb Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscle Tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Altered State of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Coordination Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysgraphia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mental Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Psychomotor Hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Slow Speech</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Tunnel Vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Visual Field Defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sensory Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Daydreaming</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dissociation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dissociative Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hallucination, Visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Illusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Merycism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Somatic Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Suspiciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thinking Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Depersonalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Persecutory Delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Micturition Urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal Dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal Mucosal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pharyngeal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pharyngeal Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper-Airway Cough Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Peripheral Coldness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

